Price
No data yet.
Social Signal Score
Revenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Amit Etkin
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 68
- Beta
- 1.16
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 20.27
Financials
Net Income
$-27.64MEBITDA
$-27.15MFree Cash Flow
$-19.76MEPS (diluted)
$-0.65Shares Outstanding (diluted)
42.81M+67.4%Operating Expenses
$29.13MCash & Debt
$243.73MReturn of Capital
$4.88MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-63.24M | $-2.19 |
| 2024 | $0.00 | $-61.43M | $-2.50 |
| 2023 | $0.00 | $-36.30M | $-1.35 |
| 2022 | $0.00 | $-27.71M | $-1.08 |
| 2021 | $210.0K | $-9.19M | $-0.36 |
Valuation
ANROhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100Social Signal Score
Mentions (1)
- Newsbusinesswire.com·5h ago·Neutral
… Neuroscience Announces Participation in Upcoming Investor Conferences MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the Company's management team will participate in the following upcoming investor conferences: H.C. Wainwright 28th Annual Global Healthcare Conference, September 1…
View source ↗
Earnings
Wed, Nov 11(in 2 months)
Consensus estimate $-0.67 per share
Typical surprise +11.5% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 12$-0.65 vs $-0.73beat
- Wed, May 13$-0.80 vs $-0.56miss
- Mon, Mar 16$-0.45 vs $-0.56beat
- Wed, Nov 12$-0.52 vs $-0.66beat
- Wed, Aug 13$-0.65 vs $-0.57miss
- Wed, May 14$-0.53 vs $-0.59beat
Estimates and results for ANRO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ANRO officers and directors.
- Bought
- $10.2m
- Sold
- —
9 trades
0 trades
- Savitz Adambought
- Savitz Adambought
- Savitz Adambought
- Smith Nicholas Conradbought
- Smith Nicholas Conradbought
- Alpha Wave Global, Lpbought
- Smith Nicholas Conradbought
- Savitz Adambought
91 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.